Current Illinois CancerCare Clinical Trials

A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients with Methylated MGMT Promoter Glioblastoma

Study Number: NRG-BN011

Study Summary:
This phase III trial compares the effect of adding lomustine to temozolomide and radiation therapy versus temozolomide and radiation therapy alone in shrinking or stabilizing newly diagnosed MGMT methylated glioblastoma. Chemotherapy drugs, such as lomustine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy photons to kill tumor cells and shrink tumors. Adding lomustine to usual treatment of temozolomide and radiation therapy may help shrink and stabilize glioblastoma.

Status: Open

RT now available at OSF- Glen Oak and SJMC.

Study Coordinator(s)
  • Navigator Carrie, 309-243-3621 cgeoffroy@illinoiscancercare.com
  • Amanda , 309-243-3663, amullery@illinoiscancercare.com
  • Jessica, 309-243-3615, jjones@illinoiscancercare.com

Study Link

« Search Again